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In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and
genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases
sensitivity to TKIs. A total of 82 NSCLC patients treated with gefitinib (250mg), and previously evaluated for EGFR and HER2 status
by fluorescence in situ hybridisation (FISH) and DNA sequencing, and for Phospho-Akt status by immunohistochemistry, were
investigated for HER3 genomic gain by FISH. Patients with high polysomy and gene amplification were considered as HER3 FISH
positive (þ). HER3 FISHþ pattern was significantly associated with female gender (P¼0.02) and never smoking history (P¼0.02).
Patients with HER3þ tumours (26.8%) had a significantly longer time to progression (3.7 vs 2.7, P¼0.04) than patients with HER3 
tumours, but not a significantly better response rate or survival. Patients with EGFRþ/HER3þ tumours had higher objective
response rate (36.4 vs 9.9%, P¼0.03) and time to progression (7.7 vs 2.7 months, P¼0.03) than patients with EGFR  and/or
HER3  tumours, but no significantly longer survival. No difference in response was observed according to HER3 status in patients
with EGFRþ tumours. Patients with HER2þ/HER3þ tumours had similar outcome as patients with HER2  and/or HER3 
tumours. Significantly different clinical end points were not observed between patients with HER3þ/P-Aktþ and HER3  and/or
P-Akt  tumours. Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients.
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Non-small-cell lung cancer (NSCLC) has been the leading cause of
cancer death in the world (Greenlee et al, 2001). Platinum-based
chemotherapy is the standard of care for advanced NSCLC, but
even with newly developed chemotherapy strategies the median
survival rarely exceeds 9 months and the fraction of patients alive
after 1 year is approximately 30% (Non-small cell Lung Cancer
Collaborative Group, 1995; Kelly et al, 2001; Schiller et al, 2002). In
recent years, several new agents able to interfere with critical
oncogenic mechanisms have been evaluated in clinical trials.
Among them, the most promising classes of compounds are those
targeting tyrosine kinases. The epidermal growth factor receptor
(EGFR), including EGFR (Erb-B1), HER2/neu (Erb-B2), HER3
(Erb-B3) and HER4 (Erb-B4), is a family of receptor tyrosine
kinases representing ideal therapeutic targets because they play a
critical role in cancer proliferation and survival (Woodburn, 1999).
A number of different ligands, including EGF, transforming growth
factor alpha and neuregulins, activate these receptors by binding to
the extracellular domain and inducing the formation of receptor
homodimers or heterodimers followed by internalisation of the
receptor/ligand complex and autophosphorylation. As a result, the
tyrosine kinase signal transduction pathways are activated
(Carpenter and Cohen, 1979; Yarden and Ullrich, 1988).
During the last decade, several new agents interfering with the
EGFR family activity have been developed (Ciardiello et al, 2003).
Among the most promising of these new drugs are gefitinib (ZD
1839, Iressa
s, AstraZeneca, UK) and erlotinib (OSI 774, Tarceva
s,
Genentech, USA). Both are orally active, selective EGFR tyrosine
kinase inhibitors (EGFR-TKI) that demonstrated anti-tumoural
activity in approximately 10% of unselected NSCLC (Fukuoka
et al, 2003; Kris et al, 2003), with a survival benefit when compared
with placebo that was statistically significant only in the case of
erlotinib (Shepherd et al, 2005; Thatcher et al, 2005). Molecular
mechanisms underlying TKI sensitivity have been recently
discovered. Patients with specific EGFR gene mutations and/or
genomic gain demonstrated to be particularly sensitive to the
inhibitory effects of TKIs (Lynch et al, 2004; Paez et al, 2004; Pao
et al, 2004; Cappuzzo et al, 2005a; Hirsch et al, 2005; Tsao et al,
2005), although a favourable prognostic role of EGFR gene
mutations cannot be ruled out (Bell et al, 2005; Eberhard et al,
Received 20 July 2005; revised 14 October 2005; accepted 17 October
2005; published online 15 November 2005
*Correspondence: Dr M Varella-Garcia;
E-mail: Marileila.Garcia@uchsc.edu
Institutions to which the work should be attributed: University of Colorado
Health Sciences Center and University of Colorado Cancer Center,
Aurora, CO, USA, and Bellaria-Maggiore Hospital, Bologna, Italy.
British Journal of Cancer (2005) 93, 1334–1340
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s2005). It is also known that EGFR mutations activated the
antiapoptotic protein Akt (Sordella et al, 2004), and that patients
whose tumours have activated Akt are more sensitive to TKIs than
patient whose tumours are phospho-AKT negative (Cappuzzo
et al, 2004).
Among the four members of the EGFR family, HER3 is unique
because of its catalytically deficient kinase domain (Guy et al,
1994) and its high propensity to self-associate in the absence of
ligand (Landgraf and Eisenberg, 2000), and the ability to assume
a locked conformation, using an intramolecular tether (Cho and
Leahy, 2002). HER3 signalling relies on heterodimerisation with
other EGFR family member, preferentially HER2 (Sliwkowski et al,
1994). Simultaneous overexpression of both HER2 and HER3 was
found in several cancers (Naidu et al, 1998; Krahn et al, 2001), and
increased drug resistance in many HER2-overexpressing cancers
depends on increased levels of HER3 or EGFR (Chen et al, 2000).
Because of the rich crosstalk among the EGFR family members,
the TKI sensitivity is not only directly dependent on the presence
of EGFR but also largely influenced by other family members,
particularly HER2. In previous studies, we observed that HER2
gene gain (Cappuzzo et al, 2005b) but not HER2 protein
expression (Cappuzzo et al, 2003) was related to gefitinib
sensitivity, and EGFRþ patients with increased HER2 gene copy
number had a significantly higher response rate, time to
progression and survival. Moreover, preclinical data indicated
that gefitinib inhibits cell proliferation by sequestration of HER2
and HER3 receptors in an inactive heterodimer configuration with
EGFR (Anido et al, 2003).
In previous studies, we also reported that activation of the
antiapoptotic protein Akt was significantly associated with
gefitinib sensitivity (Cappuzzo et al, 2004), with a significant
improvement in survival only when Akt activation was sustained
by an EGFR-dependent mechanism (Cappuzzo et al, 2005a).
Moreover, it is known that EGFR-mediated activation of Akt
requires the activation of phosphatidylinositol 3 kinase (PI3K),
and this can occur via dimerisation of EGFR with HER3, which is
able to directly couple to PI3K (Fedi et al, 1994). Finally, a recent
study showed that HER3 is used to couple EGFR to the PI3K/Akt
pathway in gefitinib-sensitive NSCLC cell lines harboring wild-type
and mutant EGFR (Engelman et al, 2005). Signalling through HER3
is fundamentally different from the other members of the HER
family since HER3 has no tyrosine kinase activity but directly
activates PI3K. Based on these data, we hypothesised that HER3
gene copy number could be relevant for gefitinib sensitivity, and
increased copy number the HER3 gene could enhance gefitinib
sensitivity in EGFRþ patients. This hypothesis was tested through
the investigation of the HER3 status by fluorescence in situ
hybridisation (FISH) in a cohort of NSCLC patients treated with
gefitinib and previously evaluated for phospho-Akt (P-Akt)
expression by immunohistochemistry (IHC), EGFR and HER2
status by FISH and DNA sequencing (Cappuzzo et al, 2004,
2005a,b).
METHODS
Patient population
NSCLC patients included in this study were treated at three Italian
institutions: Bellaria-Maggiore Hospital (Bologna), Scientific
Institute University Hospital San Raffaele (Milano) and Policlinico
Monteluce (Perugia). The cohort included 82 patients with
advanced NSCLC accrued onto the AKT prospective clinical trial
(Cappuzzo et al, 2004) or consecutively accrued from the
Expanded Access Study (EAS) of gefitinib that followed the Akt
trial. Eligibility for both studies included histologically confirmed
NSCLC with measurable, locally advanced or metastatic disease,
progressing or relapsing after chemotherapy, or medical contra-
indications for chemotherapy. Patients were classified as never
smoker, former smoker (quit smoking more than 6 months before
starting gefitinib therapy) or current smoker (quit smoking less
than 6 months before starting gefitinib therapy or active smokers).
The AKT study was approved by the Bellaria Hospital institutional
ethical review board and written informed consent was obtained
from each patient before enrollment. In the subgroup of EAS
patients, the IRB approval was obtained according to Good Clinical
Practice, and a specific written informed consent was obtained
from each patient (EAS consent form, Italian version).
Patients received gefitinib (250mgday
 1) and were evaluated
for response after 2 months according to the RECIST criteria
(Therasse et al, 2000). Tumour response was assessed by computer
tomography scan, with a confirmatory evaluation repeated in
patients with complete response, partial response, and stable
disease at least 4 weeks after the initial determination of response.
Outcome in these patients was previously reported and associated
with EGFR (Cappuzzo et al, 2005a) and HER2 status (Cappuzzo
et al, 2005b). Among the patients’characteristics, female gender
and never smoking status were significantly associated with better
response; and female gender, adenocarcinoma and bronchioloal-
veolar histology and performance status 0–1 were significantly
associated with longer survival.
No clinical or biological characteristics were used for patient
selection for this study; the single criterion considered was the
availability of tumour tissue and availability of information on
P-Akt, EGFR and HER2 FISH status.
Tissue preparation, FISH and IHC analyses
Sections from paraffin-embedded tissue blocks containing repre-
sentative malignant cells obtained at time of diagnosis were used
for this analysis. Histopathological classification was determined
on hematoxylin–eosin (HE)-stained sections based on the World
Health Organization criteria (Travis et al, 1999). The HE-stained
slide was also used as a reference for selection of tumour foci to be
analysed in the FISH assay. The HER3 FISH probe was prepared
from the BAC clone RP11-603J24; acquired from BACPAC
Resource Center (Children’s Hospital Oakland Research Institute,
Oakland, CA, USA). Single colony culture was used for amplifica-
tion of the selected DNA sequences and the extracted BAC DNA
was tested for the presence of HER3 sequences with PCR primers
as follows: forward HER3 primer: 50- GACATCAAGCA
TAATCGGCC-30; reverse HER3 primer: 50- CAGGACAAGCACT
GACCAG-30 and mapped by FISH to normal human karyotype.
HER3 DNA was labeled by nick translation reaction with
SpectrumRed-conjugated dUTP (Nick Translation Kit and reagents
from Vysis/Abbott Laboratories) according to the manufacturer’s
instructions. The CEP12 (D12Z3) SpectrumGreen probe (Vysis/
Abbott Lab, Downers Grove, IL, USA) was used as a control for
chromosome 12 aneusomy.
Dual-target, dual-color FISH assays were performed as pre-
viously described (Cappuzzo et al, 2005a), using a combination of
120ng HER3-SR, 5ng CEP12-SG per hybridisation area. Briefly,
sections were deparaffinised in CitriSolv (Fisher Scientific,
Pittsburgh, PA, USA), dehydrated in 100% ethanol, incubated in
2  saline sodium citrate buffer (2  SSC; pH 7.0) at 751C for 15–
25min, and digested with proteinase K (0.25mgml
 1 in 2  SSC;
pH 7.0) at 371C for 15–25min. After dehydration in an ethanol
series, the probe set was applied and slides were incubated at 801C
for 8–10min for codenaturation of chromosomal and probe DNA,
Hybridisation was allowed to occur at 371C for approximately 40h
and posthybridisation washes were performed in 1.5 M urea and
0.1  SSC (pH 7.0–7.5) at 451C for 30min and in 2  SSC for
2min at room temperature. After dehydration in graded ethanol
series, 406-diamidino-2-phenylindole (0.30mgml
 1 in Vectashield
mounting medium; Vector Laboratories, Burlingame, CA, USA)
was applied to the samples for chromatin counterstaining. Copy
HER3 and gefitinib sensitivity in NSCLC
F Cappuzzo et al
1335
British Journal of Cancer (2005) 93(12), 1334–1340 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
snumbers of the HER3 gene and chromosome 12 centromere probes
were assessed and recorded independently in at least 100
nonoverlapping nuclei from distinct tumour foci. Analysis was
performed independently by two observers (LT, MVG) blinded to
the patients’ clinical characteristics and other receptors’ status.
According to the frequency of tumour cells with specific number of
copies of the HER3 gene and chromosome 12 centromere, patients
were classified into two strata: HER3 FISH negative (FISH ), with
no or low genomic gain (p4 copies of the gene in 440% of cells)
and HER3 FISH positive (FISHþ), with high level of polysomy
(X4 copies of the gene in X40% of cells) or gene amplification
(presence of tight gene clusters, a ratio gene/chromosome per cell
X2, or X15 copies of the gene in X10% of analysed cells).
Statistical analysis
Differences between the FISH groups were compared by Fisher’s
exact test or w
2 test for qualitative variables and Student’s by t-test.
Normality of the distribution was assessed by Kolmogorov–
Smirnov test. Time to progression (TTP), overall survival (OS) and
the 95% confidence intervals were evaluated by the Kaplan–Meier
method (Kaplan and Meier, 1985), comparing the FISH groups by
log-rank test.
RESULTS
HER3 FISH
Among 82 NSCLC patients, no or low genomic gain for the HER3
gene (HER3 ) was found in 73.2% of cases, whereas high
polysomy and gene amplification (HER3þ) was detected in
26.8% (Figure 1). Among clinical characteristics (Table 1),
HER3þ was significantly associated with female gender
Increasing ERBB3 copy numbers
CEP 12 ERBB3
p q
1
3
.
3
1
3
.
2
1
3
.
1
1
3
.
3
1
3
.
2
1
3
.
1
1
4
1
5
2
1
.
1
2
1
.
2
2
1
.
3
2
2
2
3
2
4
.
1
2
4
.
2
2
4
.
3
1
2
4
.
3
0
2
4
.
3
3
1
2
.
3
1
2
.
2
1
2
.
1
1
1
.
2
1
1
.
1
1
1
1
2
FISH Negative ABC FISH Positive FISH Positive
Figure 1 FISH with the HER3 probe. (A) No genomic gain (pattern: disomy); (B) high gene and chromosome copy numbers and (C) gene amplification.
Table 1 Patient characteristics and HER3 FISH status in NSCLC
HER3 FISH status
Total Positive Negative
N¼82 N¼22 N¼60
Characteristics No (%) No. (%) No (%) P
Sex
Male 57 (69.5) 11 (50.0) 46 (76.7)
Female 25 (30.5) 11 (50.0) 14 (23.3) 0.02*
Age (years)
Median 61.5 59.5 62
o62 44 (53.7) 13 (59.1) 31 (51.7) 0.55
X62 38 (46.3) 9 (40.9) 29 (48.3)
Histology
Adenocarcinoma
a 43 (52.4) 12 (54.5) 31 (51.7) 0.59
Bronchioloalveolar
a 9 (11.0) 3 (13.6) 6 (10.0) P (
avs
b)
Squamous cell
b 23 (28.0) 5 (22.7) 18 (30.0)
Large cell
b 1 (1.2) 1 (4.5) 0 (0)
Undifferentiated
b 6 (7.3) 1 (4.5) 5 (8.3)
Performance status
0 43 (52.4) 12 (54.5) 31 (51.7) 0.7
1 30 (36.6) 7 (31.8) 23 (38.3) P (0+1 vs 2)
2 9 (11.0) 3 (13.6) 6 (10.0)
Smoking status
Never smoker 10 (12.2) 6 (27.3) 4 (6.7) 0.02*
Former smoker 30 (36.6) 6 (27.3) 24 (40.0) P (Never vs others)
Current smoker 42 (52.2) 10 (45.5) 32 (53.3)
*Statistically significant. HER3 FISH  corresponds to no or low gain in copy numbers
for the HER3 gene and HER3 FISH+ corresponds to high levels of gain for HER3
gene copy number (high polysomy and gene amplification).
a,bGrouping for statistics.
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s(P¼0.02) and never smoking history (P¼0.02), while no
significant association was found with age, histology, stage and
performance status.
Table 2 shows the association between HER3 FISH patterns and
response to treatment, TTP and OS after treatment. No significant
difference in overall response (OR, including complete and partial
response), disease control rate (DCR, including OR and stable
disease), TTP, and OS was observed between the two HER3 FISH
strata. In the HER3þ group, OR was 18.2% and DCR was 45.5%,
which was not significantly better than observed in the HER3 
cohort (OR¼11.7%, P¼0.47; DCR¼35%, P¼0.38). HER3þ
patients had a significantly longer TTP (3.7 vs 2.7 months,
P¼0.044), with no difference in terms of survival (10.1 vs 11.3
months, P¼0.75, Figure 2).
EGFR, HER2, P-AKT and HER3 association
Efficacy analysis Epidermal growth factor receptor and HER2
gene copy number by FISH, mutations in the tyrosine kinase
domain of the EGFR and HER2 genes by DNA sequencing and
presence of phosphorylated AKT by immunohistochemistry have
been previously determined in this cohort (Cappuzzo et al,
2005a,b). Combining those results with the current analysis, it was
verified that HER3 gene gain was observed more frequently in
patients with EGFR gene gain (P¼0.06), and HER2 gene gain
(P¼0.055), without a significant association with EGFR gene
mutations (P¼0.17) and Akt phosphorylation (P¼0.47) (Table 3).
Table 4 shows the results in terms of OR and DCR in subsets of
patient stratified according to EGFR FISH and HER3 status.
Compared to patients with tumours negative for EGFR and/or
HER3, individuals with tumours positive for both EGFR and HER3
(EGFR FISHþ/HER3þ) had a significantly higher OR (36.4 vs
9.9%, P¼0.037) and a significantly longer TTP (7.7 vs 2.7 months,
P¼0.032), with a non significant trend toward longer survival
(13.8 vs 10.1 months, P¼0.27, Figure 3). Patients with tumours
positive for both EGFR and HER3 had similar outcome than
patients EGFR FISHþ/HER3  (OR¼36.4 vs 29.4%, P¼1.0;
DCR¼63.6 vs 58.8%, P¼1.0; TTP¼7.7 vs 9.0 months, P¼0.32,
and OS¼13.8 vs 18.7 months, P¼0.85). In this study cohort, 13
patients (7 HER3  and 6 HER3þ) had tumours with EGFR gene
mutations. No difference was observed among EGFR mutationþ
patients according to HER3 status and, because of the small
Table 2 Objective response rate, disease control rate, TTP and survival analysis in NSCLC patients treated with gefitinib whose tumours showed no or
low gain in copy numbers for the HER3 gene (HER3 FISH ) and high levels of gain for HER3 gene copy number (HER3 FISH+)
HER3 FISH status
Total Pts Positive Negative
N¼82 N¼22 N¼60
Outcome No. (%) No. (%) No. (%) P-value
Total 82 (100) 22 (26.8) 60 (73.2)
Objective Response rate (OR) 11 (13.4) 4 (18.2) 7 (11.7) 0.47
Disease control rate (DCR¼OR +stable disease) 31 (37.8) 10 (45.5) 21 (35.0) 0.38
Progressive Disease 51 (62.6) 12 (54.5) 39 (65.0)
Time to progression (months) 2.9 3.7 2.7 0.044*
Median survival (months) 11 10.1 11.3 0.75
*Statistically significant.
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Figure 2 TTP and survival curves for patients with HER3þ and HER3  tumours. Median TTP and survival were 3.7 and 10.1 months in HER3þ and 2.7
and 11.3 months in HER3  (P¼0.044 and 0.75, respectively).
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snumber of patients in each group, outcome was not statistically
compared. However, responders were observed in the EGFR
mutationþ/HER3þ group (three patients) and in the EGFR
mutationþ/HER3  group (five patients).
Nine patients had tumours positive for both HER2 and HER3. In
this group of individuals, OR (33 vs 11%, P¼0.063), DCR (56 vs
36%, P¼0.28), TTP (7.7 vs 2.9 months, P¼0.1) and OS (13.8 vs
10.9 months, P¼0.63) were not significantly different from
patients with tumours HER2  and/or HER3 . Among the nine
HER2þ/HER3þ patients, only three were also EGFR FISH  and
they presented no response, the median TTP was 2.3 months, and
the median OS was 2.4 months.
Tumours from a total of 16 patients were both HER3þ and P-
Aktþ. In this group of patients, OR (25 vs 11%, P¼0.22), DCR (44
vs 37%, P¼0.62), TTP (3.7 vs 2.9 months, P¼0.20) and OS (8.3 vs
11.5 months, P¼0.72) were not significantly different than
observed in HER3  and/or P-Akt  individuals. Importantly,
among the eight cases HER3þ/P-Aktþ and EGFR FISH ,n o
objective response was detected, TTP was 2.4 months and median
OS was 6.5 months. Conversely, among the eight cases HER3þ/P-
Aktþ and EGFR FISHþ, four patients responded, two had
disease stabilisation, and only two progressed.
DISCUSSION
In the present study, we analysed the HER3 gene status by FISH in
a cohort of NSCLC patients treated with gefitinib and observed
that increased HER3 gene copy number had a low impact in drug
sensitivity. Although TTP was significantly longer in HER3þ
Table 3 Association of HER3 FISH status and EGFR FISH, EGFR
mutation, HER2 FISH and P-Akt status
HER3 FISH status
Total Pts Positive Negative
N¼82 N¼22 N¼60 P-value
Markers No. (%) No. (%) No. (%)
EGFR FISH+
a 28 11 (39.3) 17 (60.7) 0.06
EGFR FISH 
a 54 11 (20.4) 43 (79.6)
HER2 FISH+
b 21 9 (42.9) 12 (57.1) 0.055
HER2 FISH 
b 61 13 (21.3) 48 (78.7)
EGFR Mutation+
a 13 6 (46.2) 7 (53.8) 0.17
EGFR Mutation 
a 60 15 (25.0) 45 (75.0)
P-AKT+
a 52 16 (30.8) 36 (69.2) 0.47
P-AKT 
a 26 6 (23.1) 20 (76.9)
aAccording to Cappuzzo et al (2005a).
bAccording to Cappuzzo et al (2005b).
Table 4 Outcome of NSCLC patients treated with gefitinib according to the combined status of EGFR FISH and HER3 FISH
Markers Total OR (%) SD+PD (%) DCR (%) PD (%) TTP (months) OS (months)
EGFR+/HER3+
a 11 4 (36.4) 7 (63.6) 7 (63.6) 4 (36.4) 7.7 13.8
EGFR+and/or HER3+
b 39 9 (23.1) 30 (76.9) 20 (51.3) 19 (48.7) 5.9 13.8
EGFR+/HER3 
c 17 5 (29.4) 12 (70.6) 10 (58.8) 7 (41.2) 9 18.7
EGFR  and/or HER3 
d 71 7 (9.9) 64 (90.1) 24 (33.8) 47 (66.2) 2.7 10.1
EGFR /HER3+
e 11 0 11 (100) 3 (27.3) 8 (72.7) 2.7 7.3
EGFR /HER3 
f 43 2 (4.7) 41 (95.3) 11 (25.6) 32 (74.4) 2.6 8.5
P(
avs
c) 1 1 0.32 0.85
P(
avs
d) 0.037* 0.09 0.032* 0.27
P(
avs
e) 0.09 0.19 0.32 0.24
P(
bvs
f) 0.014* 0.017* 0.002* 0.25
*Statistically significant.
a-fGroups compared statistically significant.
TTP (months)
40 30 20 10 0
EGFR+/HER3+
Other
Log-rank test Log-rank test
P = 0.032
Survival (months)
EGFR+/HER3+
Other
P = 0.27
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Figure 3 TTP and survival according to HER3/EGFR FISH status. TTP and survival were 7.7 and 13.8 months in EGFRþ/HER3þ and 2.7 and 10.1
months in patients negative for HER3 and/or EGFR (P¼0.032 and 0.27, respectively).
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spatients, response rate and survival of patients with increased
HER3 gene copy number was not significantly different from the
HER3  patients. The lack of a strong association with gefitinib
sensitivity is not surprising because gefitinib is a TKI and HER3
lacks TK activity; thus, it can only signal in the context of a
receptor heterodimer. Therefore, the best way to evaluate the
impact of HER3 on gefitinib sensitivity is in combination with
other EGFR family members, particularly EGFR and HER2.
Combining the EGFR and HER3 gene status determined by
FISH, we observed that patients positive for both receptors
(EGFRþ/HER3þ) had a significantly higher response and longer
TTP, with a nonsignificant trend toward longer survival. Recent
data indicate that NSCLCs responding to anti-EGFR therapy are
likely to express HER3 at significantly elevated levels (Ono et al,
2004; Engelman et al, 2005). Moreover, preclinical data demon-
strate that gefitinib inhibits the growth of HER2 overexpressing
cells possibly by sequestration of HER2 and HER3 receptors in an
inactive heterodimer configuration with EGFR (Anido et al, 2003).
In the present study, although the better outcome was observed
among HER3þ/EGFRþ patients, the survival advantage was not
statistically significant. Importantly, regardless of the method used
for EGFR assessment (gene copy number by FISH or mutation
analysis by DNA sequencing) no difference was observed among
EGFRþ patients according to HER3 status. By contrast, our
previous analysis conducted in the same cohort of patients
demonstrated that HER2 gene increased copy number enhances
gefitinib sensitivity in EGFRþ patients (Cappuzzo et al, 2005b),
with a significant difference in outcome for patients EGFRþ/
HER2þ and EGFRþ/HER2 . These findings suggest that HER3
is less relevant for gefitinib sensitivity than HER2.
Previous data have shown that the activation of the antiapopto-
tic PI3K-Akt pathway occurs in patients with mutation in the TK
domain of EGFR (Sordella et al, 2004) or gene amplification
(Cappuzzo et al, 2005a), and Akt activation results in increased
gefitinib sensitivity (Cappuzzo et al, 2004). Because HER3 couples
EGFR to the PI3K-Akt pathway in gefitinib-sensitive NSCLC cell
lines harboring both wild-type and mutant EGFR (Engelman et al,
2005), we also investigated the correlation of HER3 with P-Akt.
Increased HER3 gene copy number was not associated with P-
Aktþ status, and the outcome of patients positive for both HER3
and P-Akt was not significantly different than patients negative for
HER3 and/or P-Akt. Although the small number of patients
precludes any firm conclusion, it is interesting to note that no
response occurred among patients EGFR /HER3þ/P-Aktþ,
while a clear benefit was observed among EGFRþ/HER3þ/P-
Aktþ patients. This finding is not surprising because sensitivity to
gefitinib is not per se depending on HER3 or P-Akt status, but is
related to the presence of the target EGFR, as demonstrated in
preclinical (Engelman et al, 2005) and clinical models (Cappuzzo
et al, 2005a,b).
Why did this study fail to demonstrate a clinical advantage for
HER3þ patients? The major difference with previous studies is
that the present report is the first conducted in gefitinib-treated
patients and not on cell lines (Anido et al, 2003; Sordella et al,
2004; Engelman et al, 2005). Another important difference is that
this investigation was performed at the genomic rather than the
protein level. Our previous findings regarding EGFR and HER2
(Cappuzzo et al, 2005a,b) showed that protein expression was
positively correlated with genomic status, but FISH results had a
higher correlation with clinical outcome than immunohisto-
chemistry results. However, it is conceivable that the same
conclusion does not apply for HER3 and epigenetic, post-
transcriptional and translational mechanisms could be responsible
for an association between higher levels of expression and
response to gefitinib. The scarce amount of tumour tissue
remaining from our patients has precluded additional analyses
to test other hypotheses. Finally, we cannot exclude that the
present study was not enough powered to detect a potential benefit
for patients with increased copy number of the HER3 gene.
In conclusion, our results suggest that increased copy number of
the HER3 gene does not significantly enhance gefitinib sensitivity
in EGFRþ NSCLC patients, therefore HER3 FISH is not likely to
be useful for selection of NSCLC patients for TKI therapy. Further
prospective studies in larger cohorts are warranted in order to
confirm these findings.
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